REVB · Revelation Biosciences, Inc. · Executive Compensation
$0.76
-0.04 (-4.67%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for June 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$3.47M
Shares
3.98M
Volume · Oct 2
43.9K
Avg daily vol (3M)
39.06K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Chester S. Zygmont, III | Chief Financial Officer | Appointed | 2026-06-24 |
| James Rolke | Chief Executive Officer | Appointed | 2026-06-24 |
| Jennifer Carver | Class A director | Appointed | 2026-06-24 |
| George Tidmarsh, M.D., Ph.D. | Class C Director | Resigned | 2025-05-28 |
| Lakhmir Chawla M.D. | Class C Director | Appointed | 2023-10-02 |
| Curt LaBelle, M.D. | Board of Directors | Resigned | 2023-10-02 |